Immuno-Oncology

BMS striving to push Opdivo past Keytruda

BMS striving to push Opdivo past Keytruda

By

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.

Merck's Keytruda is shipping

Merck's Keytruda is shipping

By

The first-in-class PD-1 was approved only last week.

Merck scores first US PD-1 approval

Merck scores first US PD-1 approval

By By

The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

By

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

BMS readies nivolumab for melanoma filing

BMS readies nivolumab for melanoma filing

By

Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy.


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION